PRNewswire - Wednesday November 8, 2000

This data will be published in the upcoming issue of the journal Cell Stress and Chaperones. Results published in this report are consistent with the clinical application of HspE7 as an immunotherapy for HPV- related diseases such as cervical and anal dysplasia and cancer. HspE7 is based on Stressgen's proprietary fusion protein platform technology.

"Stressgen's presence at this conference reflects our position at the forefront of heat shock protein based immunotherapeutics," said Dr. Marvin Siegel, Executive VP Research and Development at Stressgen. "Our data and the data of our collaborators represent the growing body of information that clearly establishes the utility of this technology as a platform to build our product pipeline."

Other presentations made by Stressgen collaborators, Richard A. Young, Ph.D., Professor of Biology, Massachusetts Institute of Technology (MIT) and a member of the Whitehead Institute for Biomedical Research and Herman Eisen, Ph.D., Professor of Immunology Emeritus, MIT, reinforce previous reports on Hsp fusion proteins mechanism of action, specifically leading to the activation of cytotoxic T cells and the production of cytokines associated with a cell mediated immune response.

Stressgen's lead product HspE7, which targets a variety of HPV-related diseases, is now in a Phase III trial for anal dysplasia. The Company also has active Phase II trials in cervical cancer and cervical dysplasia and plans to initiate a Phase II trial in genital warts. In addition, Stressgen has developed a variety of other Hsp fusion proteins for the treatment of other viral infections and related cancers, such as Hepatitis and HIV as well as asthma and allergy.

HspE7 is based on Stressgen's proprietary Hsp fusion technology. HspE7, a recombinant fusion product, is composed of heat shock protein 65 (Hsp65) from Mycobacterium-bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from the HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system attack on abnormal cells.

Stressgen Biotechnologies is a biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. Through its Biochemical Division, Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology. These products are used by scientists worldwide.

This foregoing press release may contain statements that are not based on historical fact, including, without limitation, statements containing the words "believes", "may", "will", "intends", "plans", "expects" and words of similar import. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements implied by such statements. Such factors include, but are not limited to, those with respect to the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), the Company's ability to maintain or expand its intellectual property position, the timing and success of planned or existing clinical trials and anticipated levels of revenues and expenses and others, all as described Company's Registration Statement on Form F-10 and other filings with the U.S. Securities and Exchange Commission.

SOURCE: Stressgen Biotechnologies Corp.

001108
PR001106

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .